Chen Tseng-Cheng, Wu Chen-Tu, Wang Cheng-Ping, Hsu Wan-Lun, Yang Tsung-Lin, Lou Pei-Jen, Ko Jenq-Yuh, Chang Yih-Leong
Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan.
Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan.
Oral Oncol. 2015 Nov;51(11):1004-1010. doi: 10.1016/j.oraloncology.2015.08.011. Epub 2015 Sep 11.
The treatment strategies for advanced oral squamous cell carcinoma (OSCC), especially with necrotic changes, are not effective. The programmed death ligand 1 (PD-L1) immune escape may be one of the underlying sources of resistance. Furthermore, anti-PD-L1 directed immunotherapy may be another choice for adjuvant therapy. Therefore, the expression of PD-L1 in advanced OSCC with necrotic changes is very important.
A total of 218 eligible patients with advanced stage (stage III/IV) OSCC and neck metastasis were enrolled. The presence of necrosis was reviewed by pretreatment magnetic resonance imaging. Paired paraffin-embedded primary tumor and metastatic lymph nodes (LN) sections were stained with antibodies against hypoxia-inducible factor-1α (HIF-1α) and PD-L1. Moderate-to strong HIF-1α nuclear staining in >10% and cell surface PD-L1 expression in >5% of OSCC cells were recorded as a positive result.
For advanced OSCC with necrotic changes, there was substantial agreement in primary tumor (kappa value 0.54) and almost perfect agreement in metastatic LN (kappa value 0.86) between HIF-1α and PD-L1 expression. The patients with both necrosis and positive PD-L1 expression in OSCC surrounding necrosis had worse disease control and survival outcomes. After multivariate analysis, metastatic LN necrosis and positive PD-L1 expression were found to be significant independent adverse factors.
Advanced OSCC patients with both necrosis and positive PD-L1 expression in OSCC surrounding necrosis had worse outcome. The aggressive behavior of advanced OSCC could be partially related to PD-L1 immune escape. These patients may be good candidates for anti-PD-L1 immunotherapy.
晚期口腔鳞状细胞癌(OSCC),尤其是伴有坏死改变的治疗策略效果不佳。程序性死亡配体1(PD-L1)免疫逃逸可能是耐药的潜在原因之一。此外,抗PD-L1导向的免疫治疗可能是辅助治疗的另一种选择。因此,PD-L1在伴有坏死改变的晚期OSCC中的表达非常重要。
共纳入218例符合条件的晚期(III/IV期)OSCC伴颈部转移患者。通过治疗前磁共振成像评估坏死情况。配对的石蜡包埋原发性肿瘤和转移性淋巴结(LN)切片用抗缺氧诱导因子-1α(HIF-1α)和PD-L1抗体染色。OSCC细胞中>10%出现中度至强HIF-1α核染色且>5%出现细胞表面PD-L1表达记录为阳性结果。
对于伴有坏死改变的晚期OSCC,HIF-1α与PD-L1表达在原发性肿瘤中有高度一致性(kappa值0.54),在转移性LN中几乎完全一致(kappa值0.86)。OSCC坏死灶周围同时存在坏死和PD-L1阳性表达的患者疾病控制和生存结果较差。多因素分析后,发现转移性LN坏死和PD-L1阳性表达是显著的独立不良因素。
OSCC坏死灶周围同时存在坏死和PD-L1阳性表达的晚期OSCC患者预后较差。晚期OSCC的侵袭性行为可能部分与PD-L1免疫逃逸有关。这些患者可能是抗PD-L1免疫治疗的良好候选者。